vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and PROSPERITY BANCSHARES INC (PB). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $367.6M, roughly 1.6× PROSPERITY BANCSHARES INC). EXELIXIS, INC. runs the higher net margin — 40.8% vs 31.6%, a 9.2% gap on every dollar of revenue. Over the past eight quarters, PROSPERITY BANCSHARES INC's revenue compounded faster (19.2% CAGR vs 18.7%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...
EXEL vs PB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $367.6M |
| Net Profit | $244.5M | $116.3M |
| Gross Margin | 95.6% | — |
| Operating Margin | 39.3% | — |
| Net Margin | 40.8% | 31.6% |
| Revenue YoY | 5.6% | — |
| Net Profit YoY | 74.8% | -10.7% |
| EPS (diluted) | $0.89 | $1.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | $367.6M | ||
| Q4 25 | $597.8M | $275.0M | ||
| Q3 25 | $568.3M | $273.4M | ||
| Q2 25 | $555.4M | $267.7M | ||
| Q1 25 | $566.8M | $265.4M | ||
| Q4 24 | — | $267.8M | ||
| Q3 24 | $539.5M | $261.7M | ||
| Q2 24 | $637.2M | $258.8M |
| Q1 26 | $244.5M | $116.3M | ||
| Q4 25 | $193.6M | $139.9M | ||
| Q3 25 | $184.8M | $137.6M | ||
| Q2 25 | $159.6M | $135.2M | ||
| Q1 25 | $139.9M | $130.2M | ||
| Q4 24 | — | $130.1M | ||
| Q3 24 | $118.0M | $127.3M | ||
| Q2 24 | $226.1M | $111.6M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | — |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 65.1% | ||
| Q3 25 | 37.6% | 64.4% | ||
| Q2 25 | 33.6% | 64.3% | ||
| Q1 25 | 28.8% | 62.7% | ||
| Q4 24 | — | 62.0% | ||
| Q3 24 | 25.2% | 62.1% | ||
| Q2 24 | 43.3% | 55.2% |
| Q1 26 | 40.8% | 31.6% | ||
| Q4 25 | 32.4% | 50.9% | ||
| Q3 25 | 32.5% | 50.3% | ||
| Q2 25 | 28.7% | 50.5% | ||
| Q1 25 | 24.7% | 49.1% | ||
| Q4 24 | — | 48.6% | ||
| Q3 24 | 21.9% | 48.6% | ||
| Q2 24 | 35.5% | 43.1% |
| Q1 26 | $0.89 | $1.16 | ||
| Q4 25 | $0.69 | $1.48 | ||
| Q3 25 | $0.65 | $1.45 | ||
| Q2 25 | $0.55 | $1.42 | ||
| Q1 25 | $0.47 | $1.37 | ||
| Q4 24 | — | $1.36 | ||
| Q3 24 | $0.40 | $1.34 | ||
| Q2 24 | $0.77 | $1.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $8.2B |
| Total Assets | $2.8B | $43.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | — | ||
| Q3 25 | $791.1M | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.0B | — |
| Q1 26 | $2.2B | $8.2B | ||
| Q4 25 | $2.2B | $7.6B | ||
| Q3 25 | $2.0B | $7.7B | ||
| Q2 25 | $2.1B | $7.6B | ||
| Q1 25 | $2.2B | $7.5B | ||
| Q4 24 | — | $7.4B | ||
| Q3 24 | $2.3B | $7.4B | ||
| Q2 24 | $2.1B | $7.3B |
| Q1 26 | $2.8B | $43.6B | ||
| Q4 25 | $2.8B | $38.5B | ||
| Q3 25 | $2.7B | $38.3B | ||
| Q2 25 | $2.8B | $38.4B | ||
| Q1 25 | $2.9B | $38.8B | ||
| Q4 24 | — | $39.6B | ||
| Q3 24 | $3.0B | $40.1B | ||
| Q2 24 | $2.8B | $39.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | — |
| Free Cash FlowOCF − Capex | $332.4M | — |
| FCF MarginFCF / Revenue | 55.5% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $78.3M | ||
| Q3 25 | $49.0M | $194.8M | ||
| Q2 25 | $211.4M | $98.2M | ||
| Q1 25 | $240.3M | $178.2M | ||
| Q4 24 | — | $-205.8M | ||
| Q3 24 | $271.3M | $274.6M | ||
| Q2 24 | $119.5M | $216.5M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $68.5M | ||
| Q3 25 | $46.2M | $185.7M | ||
| Q2 25 | $208.5M | $91.8M | ||
| Q1 25 | $236.3M | $171.1M | ||
| Q4 24 | — | $-210.7M | ||
| Q3 24 | $263.1M | $270.2M | ||
| Q2 24 | $113.0M | $211.8M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 24.9% | ||
| Q3 25 | 8.1% | 67.9% | ||
| Q2 25 | 37.5% | 34.3% | ||
| Q1 25 | 41.7% | 64.5% | ||
| Q4 24 | — | -78.7% | ||
| Q3 24 | 48.8% | 103.3% | ||
| Q2 24 | 17.7% | 81.8% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 3.6% | ||
| Q3 25 | 0.5% | 3.3% | ||
| Q2 25 | 0.5% | 2.4% | ||
| Q1 25 | 0.7% | 2.7% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | 1.5% | 1.7% | ||
| Q2 24 | 1.0% | 1.8% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 0.56× | ||
| Q3 25 | 0.27× | 1.42× | ||
| Q2 25 | 1.32× | 0.73× | ||
| Q1 25 | 1.72× | 1.37× | ||
| Q4 24 | — | -1.58× | ||
| Q3 24 | 2.30× | 2.16× | ||
| Q2 24 | 0.53× | 1.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
PB
| Net Interest Income | $321.1M | 87% |
| Noninterest Income | $46.5M | 13% |
